Scientists from Shanghai Zelgen Pharmatech Co. Ltd., Suzhou Zelgen Biosciences Co. Ltd. and Zejing Pharmaceutical (Zhejiang) Co. Ltd. have presented GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Scandiedge Therapeutics AB has divulged pyruvate kinase PKLR inhibitors reported to be useful for the treatment of metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma.
Scientists from Luoyang Accendatech Co. Ltd. and Tianjin Accendatech Technology Co. Ltd. have disclosed fluorine-containing parthenolide derivatives and their prodrugs reported to be useful for the treatment of cancer.
Pheon Therapeutics Ltd. has identified antibody-drug conjugates comprising antibodies targeting tumor associated antigens covalently linked to cytotoxic drugs through linker reported to be useful for the treatment of cancer.
Astrazeneca AB has synthesized nicotinamide N-methyltransferase (NNMT) inhibitors reported to be useful for the treatment of chronic kidney disease, acute kidney injury and diabetic nephropathy.
Haisco Pharmaceutical Group Co. Ltd. has prepared and tested glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes and obesity.
Wavebreak Therapeutics LLC has identified thiazole compounds acting as α-synuclein (SNCA) aggregation inhibitors reported to be useful for the treatment of amyloidosis, Creutzfeldt-Jakob disease, frontotemporal dementia, Gaucher disease, Lewy body dementia, multiple system atrophy, progressive supranuclear palsy and Parkinson’s disease, among others.
Systimmune Inc. has synthesized antibody-drug conjugates comprising antibodies targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to cytotoxic drugs through linker reported to be useful for the treatment of cancer.
RSS